Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S. Grasso, Antoni Ribas, Cristina Puig-Saus et al.|Cancer Cell|2020Cited by 379
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Adi Diab, Daniel H. Johnson et al.|Cancer Cell|2022Cited by 338
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from ImmunotherapyDaniel H. Johnson, Adi Diab|Cancer Immunology Research|2019Cited by 112
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Danai Dima, Amin H. Nassar et al.|Journal of Clinical Oncology|2023Cited by 69
The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanomaDai Ogata, Rodabe N. Amaria, Lauren E. Haydu et al.|Cancer Medicine|2021Cited by 31